Aurobindo gets tentative nod from USFDA for anti-AIDS drug
April 03, 2013  12:53
Drug firm Aurobindo Pharma today said it has received tentative approval from the US health regulator to manufacture and market its anti-AIDS combination drug Efavirenz/Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the American market. 

The company has received tentative approval from the US Food and Drug Administration for the combination drug in the strength of 600mg/200mg/300mg, Aurobindo Pharma said in a statement. 

The tablets are generic equivalent of Gilead Sciences Inc's Atripla tablets in the same strength combination and fall under the anti-retroviral segment, it added.
« Back to LIVE

TOP STORIES